Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Central Nervous System Disorders
Somaxon Present Pharmacological Data on Doxepin at the 21st European College of Neuropsychopharmacology Congress
September 20th, 2008
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, announced that data from a pharmacological profiling study relating to doxepin, the active ingredient in the company's product candidate Silenor for the treatment of insomnia, were presented yesterday at the 21st European College of Neuropsychopharmacology (ECNP) Congress. The data presented at the ECNP Congress are from a study that examined the in vitro...
Source: Law & Health Weekly (2008-09-20)
|
